Two medicines, side by side
Pitavastatin vs rosuvastatin
Pitavastatin and rosuvastatin are both labeled for high cholesterol. Drugs@FDA records approvals of pitavastatin since 2009 and of rosuvastatin since 2003. Pharmacies paid $0.954 per pitavastatin 2 mg tablet and $0.0692 per rosuvastatin calcium 40 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. How each works, in its label's words: Pitavastatin, “Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic …”; Rosuvastatin, “Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.”
Check it at the source: the pitavastatin FDA label on DailyMed (effective March 31, 2026); the rosuvastatin FDA label on DailyMed (effective September 4, 2026).
Highlights of the pitavastatin record
Pitavastatin (Livalo) · label of March 31, 2026
Used for
From the label: indicationsLIVALO is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). […]
On the market
- Earliest approval on file
- August 3, 2009
- Generic labelers
- 12 labelers
- Pharmacy cost
- $0.954 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 7
Highlights of the rosuvastatin record
Rosuvastatin (Crestor) · label of September 4, 2026
Used for
From the label: indicationsRosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events. […]
On the market
- Earliest approval on file
- August 12, 2003
- Generic labelers
- 45 labelers
- Pharmacy cost
- $0.0692 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 13
Source: FDA drug labels via openFDA (Pitavastatin label of March 31, 2026, Rosuvastatin label of September 4, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do pitavastatin and rosuvastatin differ on the record?
How each works, in its label's words: Pitavastatin, “Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic …”; Rosuvastatin, “Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.”
Both are in FDA's class HMG-CoA reductase inhibitors.
Half-life, in each label's words: Pitavastatin, “The mean plasma elimination half-life is approximately 12 hours.”; Rosuvastatin, “The elimination half-life of rosuvastatin is approximately 19 hours.”
Generics: pitavastatin since 2016; rosuvastatin since 2016 (Drugs@FDA).
| Pitavastatin | Rosuvastatin | |
|---|---|---|
| Labeled for | High cholesterol | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Pharmacologic class | HMG-CoA Reductase Inhibitor | HMG-CoA Reductase Inhibitor |
| How it works (label) | Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. | Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. |
| Half-life (label) | The mean plasma elimination half-life is approximately 12 hours. | The elimination half-life of rosuvastatin is approximately 19 hours. |
| Earliest approval on file (Drugs@FDA) | August 3, 2009 | August 12, 2003 |
| First generic approved | December 20, 2016 | April 29, 2016 |
| Generic labelers (NDC) | 12 labelers | 45 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.954 per tablet (Pitavastatin 2 mg tablet) | $0.0692 per tablet (Rosuvastatin calcium 40 mg tablet) |
| 12-month price change | -34% | -7% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 7 | 13 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 10,225 | 110,043 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to pitavastatin
- every medicine labeled for the same conditions